Option chain shows key data for Cannabiz Mobile's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cannabiz Mobile.

Cannabiz Mobile (OTC:LGBI) Stock, Option Chain

Cannabiz Mobile Inc is a mobile media and marketing company. It is engaged in servicing businesses in the medical marijuana industry. The company markets a subscription-based, in the cloud, mobile media solution to care givers, dispensaries, hydroponic, and others.

finance money crime shutter

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

News

Regulations

Commodities

General

LGBI

SHE Beverage Co claimed its bottled water could cure cancer

Beverage Share Scam Funds Casino Binges, Crypto Ponzi Scheme Get SEC&#39;s Attention: Financial Crime Weekly

cannabis Law (AJEL, lindsayfox by Pixabay)(4)

Cannabis

Legal

Anthony Jay Pignatello has been handed a final judgement by the US Attorney&#39;s Office in relation to a cannabis securities fraud scheme at Cannabiz Mobile, where he served as consultant and secretary. Pignatello was alleged to be part of a pump-and-dump scheme with Christopher Esposito, Cannabiz&#39;s former owner, whose fraudulent activities had already seen him sentenced to five years&#39; probation in November. Pignatello has been permanently restricted from being an &#34;officer or director of any issuer that has a class of securities registered under Section 12 of the Exchange&#34;, as well as permanently banned from participating in penny stocks. He is also obliged to pay $43,337, a fee that has already been deemed settled due to a parallel criminal hearing regarding securities fraud to which Pignatello had already pled guilty.

Securities Fraud Saga Comes To Close As Former Cannabiz Mobile Consultant Receives Final Judgment

Image Credits: JRByron, WilliamCho by Pixabay Edited By Benzinga

Markets

Former Cannabiz Mobile (OTCEM: LGBI) owner Christopher Esposito pled guilty on April 12 to fraud, according to the U.S. Attorney&#39;s Office, District of Massachusetts.

Former Cannabiz Boss Pleads Guilty To Securities Fraud, Sentencing Set For July

CANNABIZ MOBILE INC by Cannabiz Mobile, Inc.

Cannabiz Mobile Inc

Phoenix Motor Announces Nasdaq Delisting Notice

The participant in Neurogene's ongoing Phase 1/2 clinical trial for Rett syndrome who was dosed on November 5 with 3E15 vg of NGN-401 and was previously reported to be in critical condition, has died following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of adeno-associated virus (AAV).
Neurogene will also incorporate the 1E15 vg dose in its future registrational trial design planning.
&nbsp;
 &nbsp;

NGNE

Neurogene Says FDA Allowed Company To Proceed With Phase 1/2 Trial Using 1E15 vg Dose For Both Pediatric And Adolescent/Adult Cohorts

Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.57 by 26.32 percent. The company reported quarterly sales of $3.829 billion which beat the analyst consensus estimate of $3.812 billion by 0.45 percent. This is a 1.65 percent increase over sales of $3.767 billion the same period last year.

Earnings

Earnings Beats

Gap Q3 2024 GAAP EPS $0.72 Beats $0.57 Estimate, Sales $3.829B Beat $3.812B Estimate

Stock Split

CETX

Cemtrex Board Approves 1-For-35 Reverse Stock Split To Begin Trading November 26 Under Same CETX Symbol

Neurogene Says Participant In Ongoing Phase 1/2 Clinical Trial For Rett Syndrome Who Was Dosed On November 5 With 3E15 vg Of NGN-401 And Was Previously In Critical Condition, Has Died

CAMP

CAMP4 Therapeutics Q3 EPS $(24.19), Ended Quarter With $2.5M In Cash And Cash Equivalents

<ul>
<li>Cash and cash equivalents at €13.9 million, as of September 30, 2024.</li>
<li>Revenues of €1.3 million for the first nine months of 2024.</li>
<li>On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.</li>
<li>Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 20253.</li>
</ul>
 &nbsp;

Inventiva Reports Revenues Of €1.3 Million For The First 9-Months Of 2024

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) reported quarterly earnings of $0.37 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.146 billion which beat the analyst consensus estimate of $1.100 billion by 4.19 percent. This is a 12.35 percent increase over sales of $1.020 billion the same period last year.

CPRT

Copart Q1 2025 GAAP EPS $0.37, Inline, Sales $1.146B Beat $1.100B Estimate

Regulators are looking to block Google <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">from investing $2 billion</a> in Antrophic, a Jeff Bezos-backed rival to artificial intelligence (AI) innovator OpenAI. 
What Happened: The U.S. Department of Justice (DOJ) recommended in <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">a court filing Wednesday</a> that Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google divest its Chrome browser to dismantle its monopoly on online search. 
It doesn&#8217;t end there. Google should be barred from doing any deals with companies that control where consumers search for information, regulators say. That includes AI products. This puts Google's Anthropic investment at risk, according to <a href="https://www.bloomberg.com/news/articles/2024-11-21/us-justice-department-seeks-to-unwind-google-s-anthropic-deal">Bloomberg</a>, citing unnamed sources.
Also Read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a>
Google boasts over 91% global market share when it comes to online search, per&nbsp;<a href="https://gs.statcounter.com/search-engine-market-share" target="_blank" rel="noreferrer noopener">GlobalStats</a>.&nbsp;
Why It Matters: Google needs Anthropic, or startups like it. Without it, Google is at a disadvantage, considering every major tech company is essentially in an AI arms race. 
Since OpenAI&#8217;s ChatGPT launch in late 2022, tech giants have heavily invested in AI startups.
But Google&#8217;s Anthropic deal is raising concerns overseas as well.
Last month, U.K. antitrust officials announced an investigation into whether Google&#8217;s pursuit of Anthropic <a href="https://www.gov.uk/cma-cases/alphabet-inc-google-llc-slash-anthropic-merger-inquiry" target="_blank" rel="noreferrer noopener">could harm competition</a>. 
Meanwhile, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) managed to avoid scrutiny. <a href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog" target="_blank" rel="noreferrer noopener">The UK&#8217;s competition regulator</a> recently approved the partnership between Amazon and Anthropic, despite the Seattle-based company&#8217;s significant $4 billion investment in the company.
Britain&#8217;s Competition and Markets Authority (CMA) confirmed the partnership does not fall under its jurisdiction.
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) also appeased regulators when it <a href="https://www.benzinga.com/markets/equities/24/07/39703459/microsoft-relinquishes-observer-role-on-openais-board-says-it-is-confident-in-companys-direction" target="_blank" rel="noreferrer noopener">relinquished its board observer</a> role at OpenAI. The Redmond, Washington-based company invested over $10 billion in the AI startup.
What&#8217;s Next: A decision on whether the UK will require further investigation is expected by Dec. 19.
In the U.S., Google plans to appeal Judge Amit Mehta&#8216;s <a href="https://www.benzinga.com/government/24/08/40169996/alphabet-loses-antitrust-suit-over-google-search-dominance-report">antitrust ruling in August</a>. 
Mehta&#8217;s decision could ultimately lead to Google divesting segments of its business, <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">including Chrome</a>.
Price Action: Alphabet was down 4.5% to $169.24 on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121525/microstrategy-surges-674-in-2024-5-etfs-that-benefit-from-mstrs-bitcoin-driven-growth">MicroStrategy Surges 674% In 2024: 5 ETFs That Benefit From MSTR&#8217;s Bitcoin-Driven Growth</a></li>
</ul>
Image: Shutterstock

Politics

Tech

AMZN

GOOG

GOOGL

MSFT

Google, Anthropic Deal In Jeopardy As US Justice Department Looks To Snap Online Search Monopoly

Contracts

SNOA

Sonoma Pharmaceuticals Terminates Agreement With EMC Pharma After It Did Not Meet Minimum Purchase Requirements

Buybacks

EGAN

eGain Board Approves Extension To Stock Repurchase Program From Nov. 14 Until The Earlier Of The Date The Aggregate Amount Of Shares That Can Be Repurchased Under The Stock Repurchase Program Have Been Repurchased And November 14, 2025

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.
CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1
Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.

Biotech

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

BGC Group's Howard Lutnick To Divest Interests And Step Down From Roles At Cantor, BGC, And Newmark Pending Senate Confirmation; Corporate Structure To Remain Unchanged With John Abularrage, Jean-Pierre Aubin, And Sean Windeatt Recommended As Co-CEOs

Myers Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>), a leading manufacturer of a wide range of polymer and metal products and distributor for the tire, wheel and under-vehicle service industry (the "Company" or "Myers"), today announced that its Board of Directors (the "Board") has appointed Aaron M. Schapper as the Company's new President and Chief Executive Officer, effective January 1, 2025. Mr. Schapper will succeed Dave Basque, who has been serving as Myers' Interim President and CEO since September 9, 2024, and who will return to his role as Vice President, Special Projects. Mr. Schapper will also join the Board in January.

Management

Myers Industries Appoints Aaron Schapper As President, Chief Executive Officer And Director Effective January 1, 2025; Dave Basque, Who Has Been Serving As Myers' Interim President And CEO Since September 9, 2024, Will Return To His Role As Vice President, Special Projects

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)
IND enabling studies underway, with Phase I initiation expected in Q425

PTGX

Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease

Alta Global Group Files Request For Withdrawal Of Its Registration Statement On Form F-1 With SEC, Initially Filed On September 5, 2024

<a href="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf</a> &nbsp;

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or Within Seven Days Of FDA's New Decision

The earnings results for Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) for Q2 were made public on Thursday, November 21, 2024 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Logility Supply Chain beat estimated earnings by 22.0%, reporting an EPS of $0.11 versus an estimate of $0.09.
Revenue was down $404 thousand from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.04, leading to a 8.0% increase share price change the next day.
Here's a look at Logility Supply Chain's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.08</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.12</td>
<td>0.12</td>
<td>0.19</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>25.26M</td>
<td>25.12M</td>
<td>24.81M</td>
<td>28.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>26.19M</td>
<td>25.39M</td>
<td>25.54M</td>
<td>25.69M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Logility Supply Chain <a href="https://www.benzinga.com/quote/LGTY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGTY

Logility Supply Chain: Q2 Earnings Insights

Offerings

MODD

Modular Medical Announces Proposed Public Offering; Terms Not Disclosed

Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) announced its Q2 earnings on Thursday, November 21, 2024 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Elastic beat estimated earnings by 55.00000000000001%, reporting an EPS of $0.59 versus an estimate of $0.38.
Revenue was up $54.75 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.1, leading to a 26.0% drop share price change the next day.
Here's a look at Elastic's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.25</td>
<td>0.20</td>
<td>0.31</td>
<td>0.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.21</td>
<td>0.36</td>
<td>0.37</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>344.70M</td>
<td>329.48M</td>
<td>320.29M</td>
<td>304.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>347.42M</td>
<td>335.00M</td>
<td>327.96M</td>
<td>310.61M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Elastic <a href="https://www.benzinga.com/quote/ESTC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Cannabiz Mobile

Cannabiz Mobile (LGBI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga